Form 4: Anebulo Pharmaceuticals Director Acquires Stock Options
SEC Form 4
Jason Aryeh, a director of Anebulo Pharmaceuticals, acquired stock options for 29,964 shares on April 4, 2025.
Summary
- On April 4, 2025, Jason Aryeh, a director of Anebulo Pharmaceuticals, acquired stock options.
- The options grant the right to buy 25,000 shares at $1.02.
- An additional 4,964 options were acquired at the same price.
- The options vest on the earlier of April 4, 2026, or the date of the 2026 annual meeting of shareholders.
- The options expire on April 3, 2035.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock option grants, which is neither inherently positive nor negative. It's a neutral disclosure of information.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of management with shareholders.
Stakeholder Impact
- The granting of stock options to a director can align their interests with those of shareholders, potentially incentivizing them to increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 04/04/2025 | Date of transaction: Jason Aryeh acquired stock options. |
| 04/04/2026 | Options vest on the earlier of this date or the date of the 2026 annual meeting of shareholders. |
| 04/03/2035 | Expiration date of the stock options. |
| 04/07/2025 | Date of signature on the Form 4 filing. |
Keywords
stock options, director, ANEB, Anebulo Pharmaceuticals, Form 4, Jason Aryeh, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.